Matinas Biopharma Holdings Inc. (NYSE AMERICAN: MTNB) Stock Information | RedChip
Image

ASK REDCHAT ANYTHING ABOUT MATINAS BIOPHARMA HOLDINGS INC.

Matinas Biopharma Holdings Inc. (NYSE AMERICAN: MTNB)
Listen to this Section


$0.79
-0.0080 ( -1.00% ) 0.2K

Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others.

Clinical Trial Pipeline Stages


Drug Name Stage
MAT2203 (Oral Amphotericin B)DetailsMeningitis, Cryptococcal meningitis, Azole-resistant infections, C. krusei infection, Fungal infections, Invasive Aspergillosis Failed
LYPDISO (MAT9001) (Omega-3 Drug)DetailsCardiovascular disease Failed

Market Data


Open $0.79
Previous Close $0.80
Volume 0.2K
Market Cap $4.98M
Day Range $0.79 - $0.82
52 Week Range $0.48 - $3.09
Shares Outstanding 6.41M
Change % -1.00%
Net Change ▼ -0.0080
Insider Ownership N/A
Exchange NYSE AMERICAN
SectorHealthcare
IndustryBiotechnology: Pharmaceutical Preparations
IPO Year2014
CountryUnited States

Insider Ownership Transactions

Total Amount Purchased: -11,623,464.00

Date Type Amount Purchased Purchaser
2023-12-15 Sale -1000000.00 Liu Hui
2023-12-15 Sale -3500000.00 Jabbour Jerome D
2023-12-15 Sale -1000000.00 Hoover Thomas
2023-12-15 Sale -1200000.00 Ferguson James J. III
2023-12-15 Sale -1300000.00 Matkovits Theresa
2023-12-15 Sale -1000000.00 Kucinski Keith A
2023-11-03 Sale -437244.00 WIKLER MATTHEW
2023-11-03 Sale -437244.00 Corzo Kathryn Penkus
2023-11-03 Sale -437244.00 Scibetta James S
2023-11-03 Sale -437244.00 CONRAD HERBERT J

SEC Filings


Form Type Description Pages Date
10-q Quarterly Reports 63 Nov 10, 2025
8-k 8K-related 13 Aug 18, 2025
10-q Quarterly Reports 64 Aug 14, 2025
8-k 8K-related 13 Aug 06, 2025
8-k 8K-related 13 Jun 23, 2025

Latest News


× Before browsing our site, please accept our cookies policy